State Board of Administration of Florida Retirement System bought a new stake in Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) in the 4th quarter, Holdings Channel.com reports. The firm bought 10,136 shares of the company’s stock, valued at approximately $71,000.
Several other institutional investors and hedge funds have also made changes to their positions in KZR. Great West Life Assurance Co. Can purchased a new stake in Kezar Life Sciences during the 3rd quarter valued at approximately $26,000. Tower Research Capital LLC TRC raised its stake in shares of Kezar Life Sciences by 88.9% during the 3rd quarter. Tower Research Capital LLC TRC now owns 6,777 shares of the company’s stock worth $58,000 after buying an additional 3,190 shares in the last quarter. Robeco Institutional Asset Management B.V. purchased a new position in shares of Kezar Life Sciences during the 3rd quarter worth approximately $68,000. UBS Asset Management Americas Inc. purchased a new position in shares of Kezar Life Sciences during the 3rd quarter worth approximately $86,000. Finally, Delphia USA Inc. purchased a new position in shares of Kezar Life Sciences during the 3rd quarter worth approximately $92,000. 84.03% of the stock is owned by hedge funds and other institutional investors.
Kezar Life Sciences Price Performance
Shares of NASDAQ:KZR opened at $3.02 on Wednesday. The business’s fifty day moving average price is $2.84 and its two-hundred day moving average price is $5.38. The stock has a market cap of $218.68 million, a PE ratio of -2.85 and a beta of 0.17. The company has a debt-to-equity ratio of 0.04, a quick ratio of 19.44 and a current ratio of 19.44. Kezar Life Sciences, Inc. has a one year low of $2.25 and a one year high of $11.02.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on KZR shares. William Blair reissued a “market perform” rating on shares of Kezar Life Sciences in a research note on Wednesday, March 15th. Wells Fargo & Company lowered their price target on Kezar Life Sciences from $14.00 to $13.00 in a report on Friday, May 12th. Finally, HC Wainwright lowered their price target on Kezar Life Sciences from $21.00 to $19.00 in a report on Friday, May 12th.
About Kezar Life Sciences
Kezar Life Sciences, Inc is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
- Get a free copy of the StockNews.com research report on Kezar Life Sciences (KZR)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Want to see what other hedge funds are holding KZR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating).
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.